A letter to the editor is presented which discusses a pediatric severe aplastic anemia (SAA) transplant cohort study which evaluates the efficacy of anti-thymocyte globulin (ATG) as first-line therapy in the hematopoietic stem cell transplantation (HSCT) conditioning regimen.